8:01 AM ET
8-K
Clinical Trial Data
Oric Pharmaceuticals Clinical Trial Data
ORIC Pharmaceuticals reported updated Phase 1b data for enozertinib (ORIC-114) in patients with EGFR-mutant non-small cell lung cancer, showing an 84% confirmed systemic objective response rate. The data, presented at the ESMO Congress 2026, also highlighted significant intracranial activity and plans to initiate a global Phase 3 registrational trial in the first half of 2027.